Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company developing therapies that modulate reactive aldehyde species (RASP), a class of molecules the company links to inflammation across ocular, systemic and metabolic conditions. Its lead candidate, reproxalap, is a topical RASP modulator for the signs and symptoms of dry eye disease and allergic conjunctivitis that has received three Complete Response Letters from the FDA; the company has announced an intent to file a formal dispute resolution request over the most recent letter. The pipeline also includes ADX-2191, a preservative-free intravitreal methotrexate formulation for primary vitreoretinal lymphoma and retinitis pigmentosa, and orally administered next-generation RASP modulators such as ADX-629 and ADX-248.